SfRBM Blog

(BOSTON) – Jay Teich, former Seahorse Bioscience CEO, will receive the first ever CEO Innovator Award from the Society for Redox Biology and Medicine (SfRBM). This international award will annually recognize industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine. Teich will receive the award in Boston on November 20, 2015, during SfRBM 2015, the premier event for cutting-edge research in all aspects of redox biology. Seahorse was acquired by Agilent Technologies on Nov. 1; Teich is now general manager of the Seahorse team at Agilent.

“Led by Jay, Seahorse Bioscience has been an industry leader for many years, developing innovative technologies so many others strive to achieve,” said SfRBM president Neil Hogg, Ph.D. “We are thrilled to recognize this achievement and look forward to seeing the next chapter of scientific breakthroughs as Seahorse becomes a part of Agilent.”

Seahorse Bioscience's unique technology is the perfect complement to Agilent's market-leading separations and mass spectrometry solutions. The combination of these two platforms will give scientists a more comprehensive and faster path to researching the most challenging diseases affecting humankind, including a greater understanding of redox biology, the study of electron flow through biological circuits, sensors, and switches, applicable in many areas critical to human health including cancer, heart disease, aging, cardiovascular disease and obesity.

“I am honored to receive the SfRBM CEO Innovator Award on behalf of my colleagues at Seahorse Bioscience,” said Teich. “We are committed to developing instruments and assay kits for measuring cell metabolism, tools that provide scientists a better understanding of mitochondrial function and disease.”

About SFRBM

Founded in 1987, the Society for Redox Biology and Medicine (http://sfrbm.org) is an international organization of 1,200 scientists, investigators and clinicians who conduct research in the area of redox biology. These areas have shown explosive growth over the last decade and are now integral to major initiatives in basic, applied and translational research, including development of new therapies in cancer, heart disease, aging and cardiovascular disease.

About Seahorse Bioscience, a Part of Agilent Technologies

Seahorse Bioscience XF metabolic analyzers and stress test kits are the industry standard in cell metabolism measurements. Scientists worldwide are using Seahorse technology to advance their research in understanding the role of cell metabolism. Seahorse is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark, and Shanghai, China. For more information, visit www.seahorsebio.com. Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. For more information, visit www.agilent.com.